ADICET BIO INC (ACET) Stock Price, Quote, News and Overview
NASDAQ:ACET - Nasdaq - US0070021086 - Common Stock - Currency: USD
ACET Quote, Performance and Key Statistics
0.5858
-0.03 (-4.62%)
The current stock price of ACET is 0.5858 USD. In the past month the price decreased by -31.08%. In the past year, price decreased by -65.13%.
ACET Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About ACET
Company Profile
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. The company is headquartered in Boston, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-01-26. The firm is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Company Info
ADICET BIO INC
131 Dartmouth Street, 3Rd Floor
Boston MASSACHUSETTS 02116 US
CEO: Chen Schor
Employees: 143
Company Website: https://www.adicetbio.com/
Investor Relations: https://investor.adicetbio.com/
Phone: 16174822333
ADICET BIO INC / ACET FAQ
What is the stock price of ADICET BIO INC today?
The current stock price of ACET is 0.5858 USD. The price decreased by -4.62% in the last trading session.
What is the ticker symbol for ADICET BIO INC stock?
The exchange symbol of ADICET BIO INC is ACET and it is listed on the Nasdaq exchange.
On which exchange is ACET stock listed?
ACET stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ADICET BIO INC stock?
14 analysts have analysed ACET and the average price target is 6.53 USD. This implies a price increase of 1014.37% is expected in the next year compared to the current price of 0.5858. Check the ADICET BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADICET BIO INC worth?
ADICET BIO INC (ACET) has a market capitalization of 48.44M USD. This makes ACET a Nano Cap stock.
How many employees does ADICET BIO INC have?
ADICET BIO INC (ACET) currently has 143 employees.
What are the support and resistance levels for ADICET BIO INC (ACET) stock?
ADICET BIO INC (ACET) has a support level at 0.53 and a resistance level at 0.62. Check the full technical report for a detailed analysis of ACET support and resistance levels.
Should I buy ADICET BIO INC (ACET) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACET, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACET, evaluating the profitability, health, valuation and growth aspects
- ADICET BIO INC (ACET) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADICET BIO INC (ACET) Sales and EPS estimates to see what analysts future expectations are.
- ADICET BIO INC (ACET) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADICET BIO INC (ACET) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADICET BIO INC (ACET) Stock Chart to make your own analysis
- ADICET BIO INC (ACET) Latest news and press-releases to stay up to date.
Does ADICET BIO INC (ACET) stock pay dividends?
ACET does not pay a dividend.
When does ADICET BIO INC (ACET) report earnings?
ADICET BIO INC (ACET) will report earnings on 2025-05-12, after the market close.
What is the Price/Earnings (PE) ratio of ADICET BIO INC (ACET)?
ADICET BIO INC (ACET) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.34).
What is the Short Interest ratio of ADICET BIO INC (ACET) stock?
The outstanding short interest for ADICET BIO INC (ACET) is 4.13% of its float. Check the ownership tab for more information on the ACET short interest.
ACET Technical Analysis
ACET Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACET. No worries on liquidiy or solvency for ACET as it has an excellent financial health rating, but there are worries on the profitability.
ACET Financial Highlights
Over the last trailing twelve months ACET reported a non-GAAP Earnings per Share(EPS) of -1.34. The EPS increased by 59.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.93% | ||
| ROE | -55.73% | ||
| Debt/Equity | 0 |
ACET Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ACET. The Buy consensus is the average rating of analysts ratings from 14 analysts.